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Reactive oxidizing species are implicated in the etiology of a range of inhalational pulmonary
injuries. Consequently, various freeradicalscavengershavebeentested aspotentialprophylacticagents.
The sulfydryl compound,N-acetylcysteine (NAC) istheonly suchcompound clinicallyavailable foruse
inrealistic dosages, anditiswellestablishedasaneffectiveantidote forthehepatic andrenaltoxicity
ofparacetamol. Another approach in pulmonary injury prophylaxis is methylprednisolone therapy.
We evaluated NAC and methylprednisolone in two rat models of inhalational injury: 40-hr exposure
to >97% oxygen at 1.1 barand 15-minexposure toacrolein vapor (210 ppm). For oxygentoxicity, NAC
(80 mg) ormethylprednisolone (10 mg) were given IP every 2 or 6 hr, respectively. For acrolein, single
doses ofNAC (1 g/kg) and methylprednisolone (30 mg/kg) were given intravenously 15 min before ex-
posure. Insham-exposedcontrolanimals, neithertreatmentfavorablyeffectedmortality, lungwet/dry
weightratios, orpulmonaryhistology. Theincreasesinlungwet/dryweightratios, seenwithbothoxy-
genandacroleintoxicitywerereducedwithbothtreatments. However, withoxygen, NACtherapy was
associated with considerably increased mortality and histological changes. Furthermore, IP NAC ad-
ministration resulted inlargevolumes ofascitic fluid. Withacrolein, IV, NAChadnosignificanteffect
onmortality orpulmonaryhistologicaldamage. Methylprednisolone hadnobeneficialeffectsoneither
the mortality orhistological damage observed in eithertoxicity model. We cautionagainst the ad hoc
use of NAC in the management of inhalational pulmonary injury.
Introduction
Reactive oxygen species resulting in oxidant-
antioxidantimbalanceinthelunghavebeenimplicated
in the pathogenesis of a number of inhalational
pulmonary injuries. Hyperoxia leadstothe formation of
reactivespeciesofoxygenat aratethatoverwhelmsthe
natural defense mechanisms of the pneumocytes. The
reactive species include superoxide (O 2 ) and hydrogen
peroxide (H202) that maytheninteract, resulting inthe
extremely reactive hydroxyl (OH,) radical (1). Singlet
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oxygen ('02) can also be produced, which like the
hydroxylradical, caninitiatedestructivelipidperoxida-
tion of cell membranes (2,3).
Pneumoprotection against such reactive species
depends onthe cells' antioxidant defense mechanisms,
whichinvolvevitaminsE andC,13-carotene, superoxide
dismutase, catalase, and the glutathione peroxidase
system(4). Thelatterisakeyenzymeforthe detoxifica-
tionoflipidperoxides, andthemaintenance ofreduced
glutathione isessentialforitsfunction. Acrolein, ahighly
reactive aldehyde gas that is a conspicuous component
ofmanyharmfulfiresmokes, issimilarlyinactivated by
glutathione conjugation (5).
Several thiol compounds have been shown to protect
tissues against oxygen toxicity, either by supporting
glutathionebiosynthesisorbyactingasdirectscavengers
ofreactiveelectrophilicspeciesviathechemicalreactiv-
ity of their thiol group (6-9). Four years ago we began
a series of experiments to see whether the clinicallyCRITCHLEYETAL.
available thiol-containing drugN-acetylcysteine (NAC)
hadapotentialrole intheprophylaxisandtreatment of
oxygen and other forms of pulmonary toxicity such as
that from acrolein and phosgene inhalation. NAC has
been used for its mucolytic properties for many years
and, morerecently, hasbecomewellestablishedastreat-
ment for oral paracetamol poisoning (10).
Arelativelyminorpathwayofparacetamolmetabolism
involves cytochrome P-450-dependent microsomal
enzymes and leadstotheformationofahighlyreactive
intermediate. In normaldosage, thisisharmlessly inac-
tivatedbycombinationwithreducedglutathione. How-
ever, following overdosage, the glutathione peroxidase
system is overwhelmed and severe hepatic and renal
damagecanoccur. TheadministrationofIVororalNAC
within8hroftabletingestioneffectivelyprotectsagainst
such tissue damage by either replenishing reduced
glutathione stores or combining directly with the toxic
intermediate (11).
NAChasprovenextremelysafe and free fromsideef-
fects, despite the large IV doses that are given to treat
paracetamol poisoning: 150 mg/kg over 15 min, fol-
lowed by 50 mg/kg over the next 1 hr, and then 100
mg/kgover 16hr(12). Morethan 1 g/kgcanbetolerated
parenterally by rodents (13).
NAC was, and still is, the only free radical scavenger
clinicallyavailableforintravenoususageindosageslike-
ly tobe effective. Thus, although there are theoretical-
lymoreeffectivescavengersavailableinthelaboratory,
thesearemanyyearsofdevelopmentawayfromroutine
clinical usage. Consequently, we considered that there
wasapressingneedforNACtobeevaluated inananimal
model, thus mimicking its possible therapeutic use in
manforthepreventionofoxygenandotherformsofin-
halational pulmonary toxicity.
Using rats, our oxygen toxicity model was 40 hr of
oxygen (> 97%) with the rats breathing at 1.1 bar. We
chose acrolein as the noxious gas, and exposed rats to
210 ppm for 15 min. In both models, we compared the
effect ofNAC treatment with methylprednisolone that
had been previously shown in rabbits to decrease mor-
tality following acrolein inhalation (14).
Unfortunately, our results with NAC were very dis-
appointing. Although NAC appeared relatively non-
toxic on its own, it potentiated toxicity in both the
models. Recently, however, there has been increasing
evidence of the beneficial effects of NAC in isolated
tissuemodels(9)andeveninwholeanimals. Onereport
suggested itreducedthemortalityfrom 7daysofoxygen
breathing (8), and another report alleged a protective
actionofNACagainsthyperbaricoxygenexposurebased
on reduced increases in lung wet and dry weights (15).
Somewhat alarmingly, the possible involvement of
reactivespeciesintheiretiologyhasresultedinthesug-
gested and actual use of NAC for various lung path-
ologies, ranging from cystic fibrosis to bleomycin and
zinc chloridetoxicity(15-17). Theuseofanunsubstanti-
ated therapy is understandable when treating a life-
threateningcondition, providingthetherapyissafeand
will notexacerbatetheunderlyingpathology. However,
theresultsthatwe nowpresentbelowindicatethatthis
may not be the case with NAC.
Methods
ThestudieswereconductedattheAdmiraltyResearch
Establishment (Alverstoke, UK) and the Chemical
DefenceEstablishment(PortonDown, UK)underUnited
Kingdom Home Office licenses to experiment on living
animals; theyweredesignedtoensurethattheminimum
number of animals was used to obtain meaningful
results. The conduct of the studies was in accord with
thatrecommendedintheNIHreportGuidefortheCare
and Use ofLaboratory Animals (18).
Wistarratsweighing200to250gwereused.Theywere
housed six to a cage and were given food and water ad
libitum.
Pulmonary Insults
OxygenExposure. Exposurewasachievedbykeep-
ing the caged rats in the two-man airlock of a ten-man
therapeutic recompression chamber. The oxygen con-
centrationwaskeptabove97% andapressureof1.1 bar
was maintained for40 hr. Control animals were kept in
cages placed in the airlock of an identical ten-man
chamber that was open to the atmosphere (i.e., sham
exposure).
AcroleinExposure. Ratswereplacedingroupsof 12
in a 50-L exposure chamber, and acrolein vapor was
generatedbyinjectingacrolein(BritishDrugHousesLtd.)
through an atomizerinto the inflowsupply ofairtothe
chamber. The volatility of acrolein is such that the
evaporationofthefine aerosolis almostinstantaneous.
Previousexperienceestablishedthatthemixingproper-
ties ofthe chamber were such that the concentrations
of acrolein rose to the desired level within a minute of
delivering the substance into the atomizer. Concentra-
tions of acrolein vapor during the 15-min exposure,
measured usingon-lineinfraredgasanalysis, rangedbe-
tween 207 to 214 ppm (476-514 mg/m3). The control
animalswereplaced inthe chamberbut notexposed to
acrolein (i.e., sham exposure).
Treatments
NACAdministration. Parvolex(Duncan, Flockhart
&Co. Ltd.)formulatedforIVadministrationtomanwas
used.
OXYGEN TOXICITY EXPERIMENTS. Twelve rats received
80 mg ofNAC (0.4 mL) IP every 2 hr during the course
of oxygen exposure. The injections were completed
within 10 min, and the oxygen concentration in the
chamber returned to over 97% within a further 5 min.
Another 12ratsreceived0.4mL0.9% salineIPevery2 hr
during oxygen exposure.
ACROLEIN INHALATION EXPERIMENTS. Twelve rats
received a single 1-g/kg dose of NAC IV 15 min prior
to acrolein inhalation. Another twelve rats received
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0.9% saline (5 mL/kg) IV 15 min prior to acrolein
inhalation.
MethylprednisoloneAdministration. OXYGENTox-
ICITY EXPERIMENTS. Twelve rats received 10 mg of
methylprednisolone IP every 6 hr during oxygen
exposure.
ACROLEIN INHALATION EXPERIMENTS. Twelve rats re-
ceived asingledoseof300mg/kgofmethylprednisolone
IV 15 min prior to acrolein inhalation.
Control Animals. Controls are defined as the rats
given one of the three treatments (NAC, methylpred-
nisolone, orsaline)butreceivingonlysham exposure to
eitheroxygen oracrolein. There werefouranimalsinthe
threetreatment groupsforeachtypeofsham exposure,
exceptfor 12 inthesham oxygen exposure groupreceiv-
ing IP NAC.
Assessment Criteria
Premature Mortality. OXYGEN TOXICITY EXPERI-
MENTS. During exposure to high concentrations of
oxygen, the rats were observed at the injection times
every 2 hr. Times of premature death were noted and
the animals were assessed as described below. The
animals were sacrificed at the end ofthe 40-hr oxygen
exposure period and were treated like those that had
died spontaneously.
ACROLEIN INHALATIONEXPERIMENTS. Followingacrolein
inhalationtherats wereobserved at2-hrintervals. Times
ofpremature death were noted andthe animals assess-
ed as described below. At 24 hr, the surviving animals
weresacrificed andtreatedin asimilar mannertothose
that had died spontaneously.
Lung Preparation. After opening the chest, the
pleuralcavity wasexaminedforthe presenceoffluidand
volumes greater than 0.2 mL were removed for subse-
quent analysis for osmolarity and protein content.
Thetrachea wascannulated, aligature placedaround
the root of the main lobe ofthe left lung, and this lung
removed. The lung wasplaced on apreviously weighed
pieceoffoil, weighed, andthendriedin an oven(120(C,
inair)for24hrbeforebeingreweighed. Thelungwet/dry
weight ratio was then calculated.
Immediately after removal of the left lung, the right
lung was inflated in situ with modified Millonigs
phosphate-buffered formalinforcedthroughthetrachea
until it was distended to a size equivalent to normal in-
spiratory expansion. This was achieved by exerting a
pressureof20to25 cmofH20. Thetrachea wasligatured.
After removal from the animal, the larynx, trachea,
heart, andlungwereimmersedinthe samefixative. The
right lung was sectioned horizontally into slices 0.5 cm
thick. Eachslice wasimbeddedinparaffinand section-
ed for light microscopy using hematoxylin and eosin
staining.
HistologicScoringofLungs. A system ofquantify-
ing lung damage was developed so that the extent and
severityofchangesinthelungsofdifferentanimalscould
be compared (14). Specified histopathologic features
were each scored in every lung slice according to the
criteriashownin ilible 1. The scoresforeachslice were
tabulated andtotaled; foreach lung, the meantotalfor
all the slices combined was calculated (14).
PeritonealFluid. The abdomen was also opened. If
asignificant volume ofperitonealfluid was present, its
volume was measured.
Results
Results forthe groups are given as means + standard
deviations, but they were compared by the non-
parametricMann-Whitney(Wilcoxon)two-sample rank
sum test unless otherwise stated.
Premature Deaths
Thepercentage ofprematuredeaths, i.e., those occur-
ringbeforetheexperiments weretenninatedbysacrifice
ofallthesurvivinganimals, isshownforeachtreatment
group in Figure 1. No premature deaths nor deteriora-
Table 1. Lung histologic scoring.a
Severity score
Histological feature 0 1 2 3
Bronchial wall Normal Surface damage Partial necrosis Complete necrosis
Alveolar wall Normal Cells desquamated Focal necrosis or Confluent necrosis or
hemorrhage hemorrhage
Pulmonary edema Absent Interstitial Alveolar Confluent
Vascular congestion 3 Perilart ionflmtion Absent Mild Moderate Severe Periarterial inflammation
Area score
Whole slice One-third slice One- to two-thirds Two-thirds to whole
normal damaged damaged slice damaged
aLung histologic scoring: The discriminatory features used for the final scores are shown. The score for each histologic slice was ob-
tained by multiplying the severity score by the area score. These scores for each slice were tabulated, totaled, and the mean total for
each lung calculated.
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FIGURE 1. Premature deaths (mortality) expressed as a percentage
ofthetotalnumberofanimalsineachofthethreetreatment groups.
Oxygen-exposed (O) and acrolein-exposed (O) groups are shown
asseparate histograms. All three treatments are combined forthe
control (sham-exposed) data.
tion in gross clinical appearance occurred in any ofthe
sham-exposed control groups, indicatingthatbothNAC
andmethylprednisolone alone werefairly welltolerated.
With oxygen exposure, premature deaths only occur-
red in the animals receiving NAC, and the mortality of
8outofthe 12animals-comparedwith nodeathsinthe
other groups-was significant (p <0.05) by a chi-square
test. The NAC group deaths occurred between 36 to 40
hr, andthesurvivinganimalsalllooked veryunwell, com-
pared with those in the other two oxygen-exposed
groups.
With acrolein exposure, premature deaths were seen
in all three treatment groups. The lowest mortality was
inthe NAC treatment groups. The lowest mnortality was
less than half that in the other two groups, it was not
asignificantdifferenceby achi-squaredtest. The mean
times of premature death with their ranges were 11
(5-14)hr, 12 (11-13)hr, and 14.5(6-21) hrforthe saline,
NAC, and methylprednisolone groups, respectively.
Pleural Fluid
Significant amounts ofpleural fluid were only found
in the rats exposed to oxygen, and the mean volumes,
osmolarities, and total protein contents are given in
lhble 2. The sham-exposed control rats in the oxygen
experimentandthe ratsintheacroleinexperimenthad
no significant pleural fluid.
Peritoneal Fluid
Significant amounts of peritoneal fluid were only
foundinthoseanimalswhichhad received IPNAC. The
meanvolumesintheoxygen-exposed andsham-oxygen-
exposed control animals were 18 + 16 and 28 + 19 mL,
respectively.
Lung Wet/Dry Weight Ratios
The mean wet/dry weight ratios expressed as a per-
centage ofthe meanratiosfromthesham-exposed con-
trol animals for each pulmonary insult are given in
Figure 2. The treatments alone had no favorable effect
on the ratio. Thus, for the oxygen and acrolein sham
exposures, thedatafromthethree groups werecombin-
ed to give the mean control values and then were ex-
pressed as 100%.
Oxygen exposure resulted in a highly significant in-
creaseinthewet/drylungweightratios(p = <0.0001),
suggestingthe presenceofpulmonaryedema. Withboth
theactivetreatmentsthe meanratios werelessthanwith
saline. This difference was not significant for NAC but
was significant for methylprednisolone (p = < 0.05).
Acrolein exposure resulted in a small increase in the
meanwet/drylungweightratiothat wasnot seeninthe
two groupsreceivingactivetreatments. Thus, the mean
ratios in the NAC and methylprednisolone groups
were significantly less than that of the saline group
(p = < 0.05 and < 0.01, respectively).
TIble 2. Pleural fluid in rats exposed to oxygen for 40 hr.
Treatment (number of rats) Volume, mL Osmolarity, mOsm/kg Protein, g/L
Controls (20)a b (sham exposure) < 0.2
Saline (12) 4.4 + 2.6 293 + 17 42 + 4
NAC (12) 1.3 +
0.9c 339 + 30c 41 + 5
Methylprednisolone (12) 6.2 +
1.2c 366 + 45c 49 + 4c
aThe three treatment groups combined.
"'Significantly different from saline treatment group; p = < 0.01 by the Mann-Whitney (Wilcoxon) two-sample rank sum test.
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FIGURE 2. Mean (± SD.) rat lung wet/dry wt ratios expressed as a
percentage ofthecontroldataforeachofththreetreatmentgroups.
Oxygen-exposed (E) and acrolein-exposed (U) groups are shown
asseparate histograms. Allthree treatments arecombinedforthe
control (sham-exposed) data which is plotted as 100%.
Lung Histology Scores
The means ofthe individual lung mean totals for the
histology scores are given in Thble 3. The methyl-
prednisolone data areincomplete, butthefullhistology
data aretobepublished in asubsequent paper. The tox-
iceffectsofboth oxygenandacrolein exposure areclear.
All the treatment groups for acrolein exposure had
equally severe laryngeal damage that was not seen
following oxygen exposure. This and bronchial wall
damage weremajorfeaturesofacrolein exposure, unlike
the oxygen exposure where alveolar damage was a
distinctive feature. General tissue edema and vascular
congestion wereprominentfeaturesofbothpulmonary
insults.
Neither of the active treatments alone (i.e., in sham-
exposed animals) appeared to have an effect on lung
histology. However, NACtreatmentappearedto exacer-
bate, markedly, the toxic effects of both oxygen and
acrolein. Withoxygen exposurethisdifference(fromthe
saline group) was highly significant (p = < 0.01).
Discussion
Both ourpulmonaryinsultregimensproduceddefinite
lunginjury, based onhistological criteria, andsignificant
increases in lung wet/dry weight ratios.
Thehistologicalchanges werequalitativelydifferent.
Oxygen exposurecausedpredominantalveolardamage,
whilesubstantiallaryngealandairwayedemafollowed
acrolein exposure. This explains the different patterns
ofpremature mortality. While none ofthe animals died
prematurelywith oxygen exposure alone, when exacer-
bated by the NAC therapy, the clinical condition of all
theanimalssteadilydeteriorated overthe40-hrexposure
period and8ofthe 12 diedprematurely after36hr. The
survivorslooked very unwell and hypoxic, suggesting a
significant impairment in alveolar gas exchange.
However, although acrolein exposure resulted in a 50%
premature mortality, the deaths tended to occur early,
and the surviving animals looked fairly well. This
exposureiscompatiblewithdeathresultingfrom upper
airwayobstructionsecondarytoedemaandlessgeneral-
ized alveolar damage.
NACtreatment, contrarytoprotectingagainstoxidant
lungdamage, actually appeared to exacerbate it on the
basisofhistologicalcriteria, and-in the case of oxygen
toxicity-a dramatic increase in mortality. Variable
results have been reported using vitamins E and C,
superoxidedismutase, andsulfhydrylcompoundsto pro-
tect against oxidants (4, 6-9, 15-20). Favorable effects
withNAC orcysteaminehavebeendescribedbutseveral
are based on reduced lung wet weights (8,15,21) or
pleural fluid volumes (21). We also found significant
reductionsinlungwetweightsandpleuralfluidvolumes
using NAC treatment, despite increased histological
damage; these findings suggest that these changes
may be a consequence of an osmotic ordehydrating ef-
fect of the treatment. The smaller volumes of pleural
fluid with NAC treatment had a significantly higher
osmolarity than those from the saline-treated, oxygen-
exposed animals.
Tasble 3. Lung histology scores: means ± SD of individual lung mean totals.
Treatment (number of rats) Oxygen exposure Acrolein exposure
Control (16, 12)a (sham exposure) 3 + 1 2+ 1
Saline (12,12) 10 + 4C 10 + 9c
NAC(12,12) 17 + 6C 16± 5C
Methylprednisolone (12) - 8+ 8C
aThe respective treatment groups combined.
bSignificantly different from controls (p = < 0.01).
cSignificantly different from controls and saline group; p = < 0.01 by the Mann-Whitney (Wilcoxon) two-sample rank sum test.
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Patterson and coworkers (8) reported a reduction in
mortalityfrom78to28% whentreatingratswith7days
of99% oxygenexposure'andwithcontinuous infusions
ofNACinadoseof390mg/kg/day, buttheydidnotper-
form lung histology. Their results were less favorable
when the dose was increased to 600 mg/kg/day (mor-
tality 43%).
We chose higher doses still, which may explain why
we encountered adverse effects onmortality thatwere
possibly due toNAC actingasan electron donorat high
concentrations in an environment rich in reactive
species. Fromourcontroldata, thesehighdosesofNAC
did not appear toxic in the absence of an oxidant
pulmonary insult.
Fortheoxygentoxicitystudy, theNACdosewasbased
on the initial dose used to treat paracetamol poisoning
in man. The frequency ofadministration was based on
the short half-life of sulfhydryl compounds in plasma.
Our pilot experiments revealed that the elevated sulf-
hydryl group activity following IV NAC administration
fell rapidly with a half-life of less than 1 hr when
measured by a 5,5' -dithiobis-(2-nitrobenzoic acid),
(DTNB)basedassay(22). Similarresultshadbeenobtain-
edinmanusinganHPLCassay(D. R. Jarvie, unpublish-
ed observations). Since IV administration would have
beenimpractical inouroxygentoxicity model andNAC
therapy is effective orally in man, we gave the NAC by
IPinjections at intervals of2 hr. Although this regimen
alonedidnothaveanynoticeableeffectsonthegeneral
condition of the animals or their lungs, it did result in
a local reaction as manifested by the accumulation of
large volumes of peritoneal fluid.
We did not confirm the favorable action of methyl-
prednisolone on the mortality from acrolein exposure
reported by Beeley and coworkers (14). As the latter
workers found, methylprednisolone did not reduce the
amountofhistologicaldamage. Ontheotherhand, itdid
result in significant reductions in lung wet/dry weight
ratioswithbothacroleinandoxygenexposure. However,
thevolumesofpleuralfluidandtheirosmolarityandpro-
tein content were significantly increased with methyl-
prednisolone in the oxygen toxicity experiments.
The value ofmethylprednisolone in the treatment of
oxidant-type pulmonary insults remains an open ques-
tion. However, ourresultssuggestthatNACadministra-
tionmayexacerbatethelungdamagefromsuchinsults,
and we caution against its indiscriminate or ad hoc use
in man.
We thank Surgeon Commander John D. Buchanan, Royal Naval
Hospital, Haslar, Gosport, Hampshire, UK, for the histological ex-
amination of the rat lungs.
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